Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Incyte ( (INCY) ) has provided an update.
On May 11, 2025, Incyte Corporation and Novartis Pharma AG reached a settlement agreement concerning a litigation over royalty payments related to JAKAFI sales in the United States. Incyte agreed to pay Novartis $280 million for disputed royalties and to reduce future royalty rates by 50% starting January 1, 2025, impacting the company’s financial statements for the quarter ending June 30, 2025.
The most recent analyst rating on (INCY) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Incyte stock, see the INCY Stock Forecast page.
Spark’s Take on INCY Stock
According to Spark, TipRanks’ AI Analyst, INCY is a Outperform.
Incyte’s overall stock score of 75 reflects its strong financial performance and a positive outlook from the recent earnings call, which highlighted significant revenue growth and successful product launches. These strengths are somewhat offset by the technical analysis indicating potential bearish trends and a high P/E ratio suggesting overvaluation. While the company is financially stable, improving profitability margins could further enhance its stock performance.
To see Spark’s full report on INCY stock, click here.
More about Incyte
Incyte Corporation operates in the biopharmaceutical industry, focusing on the discovery, development, and commercialization of proprietary therapeutics. The company is known for its product JAKAFI, which is used in the treatment of various conditions.
Average Trading Volume: 2,025,418
Technical Sentiment Signal: Sell
Current Market Cap: $11.78B
For detailed information about INCY stock, go to TipRanks’ Stock Analysis page.